myFibroScan vs iCyst

FibroScan® is the non-invasive gold standard solution for comprehensive management of liver health. FibroScan® is powered by three unique, patented and validated biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 5300+ peer-reviewed publications and 180+ international guidelines. myFibroScan app is your everyday FibroScan® companion to access Interpretation Guide and FibroScan® based scores in an easy, fast and intuitive way : The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting FibroScan® examination results. Scores enhance FibroScan® liver disease assessment with biological markers. Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions. • Fast is an aid to identify at risk MASH patients defined as MASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (MASLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast. • Agile 3+ is an aid to identify MASLD patients with advanced fibrosis by combining LSM by VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins. • Agile 4 is an aid to early identify MASLD patients with cirrhosis by combining LSM by VCTE™ and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin. MASH Treatment Eligibility Tool to eliminate the Guesswork. This patient management tool embeds treatment recommendations based on the patient’s FibroScan® results and the latest AASLD Guidance.

COMPLETE THE SURVEY ON PANCREATIC CYSTIC NEOPLASMS (https://pancreasverona-ebm.bluemilk.cloud/guidelines-on-pancreatic-cystic-tumours), GET THE REGISTRATION CODE AND UNLOCK ALL FEATURES OF THE APP. iCyst – Improving Clinical Practice for Pancreatic Cystic Neoplasms, give direct access to up-to-date European, International Association of Pancreatology (IAP) and American Gastroenterological Association (AGA) guidelines for the management of pancreatic cystic neoplasms. You can quickly navigate through guidelines and flowchart. Insert all cyst’s features to get recommendations from the three different guidelines thanks to a built-in algorithm (feature available only after completing the survey in the above link). The app contains the following guidelines: European evidence-based guidelines on pancreatic cystic neoplasm (2018) Revision of the International Association of Pancreatology (2017 update) American Gastroenterological Association guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cyst (2015) The user can navigate the guidelines both in PDF and flowchart format. With iCyst the user can select cyst’s characteristic to assess the standard of treatment according to each guideline and select which of the guideline will be followed. Data can be saved anonymously and stored to be checked again or modified. Get updated, disseminate guidelines for the management pancreatic cysts and improve your clinical practice!